Characteristics of Intestinal Bacteria and Their Effects on Growth and Immune Function in Children at High Altitude
Launched by RUIJIN HOSPITAL · Nov 27, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how the bacteria in the intestines of young children living at high altitudes affect their growth and immune system. Researchers want to understand how the unique environment of high altitudes, along with different diets, influences the types of bacteria present in children's guts. By comparing these children to those living at lower altitudes, the study aims to find out how these bacteria help with immunity, metabolism, and overall growth. This information could help improve the health of children living in high-altitude areas.
The trial is looking for children aged 1 to 3 years old, and both boys and girls can participate. To be eligible, a child's legal guardian must agree to let them join and follow the study's guidelines. However, children who have taken probiotics or antibiotics in the past month, or who have certain health issues, may not be suitable for this study. Participants can expect to contribute to important research that could lead to better health outcomes for children in their communities.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children aged 1-3 years old
- • Both men and women;
- • The child's legal guardian signed the informed consent to participate in the study.
- • The legal guardian of the child commits to follow the study procedures and cooperate with the entire study process
- Exclusion Criteria:
- • Probiotics or antibiotics within 1 month
- • Associated with clinically significant abnormalities in liver and kidney function, nervous system, respiratory system, and coagulation function as determined by the investigator
- • Unstable vital signs;
- • Have other underlying medical conditions
- • Individuals deemed unsuitable for this clinical trial.
About Ruijin Hospital
Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, is a leading medical institution in China recognized for its commitment to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care, Ruijin Hospital integrates cutting-edge medical practices with rigorous scientific investigation. The hospital's multidisciplinary teams are dedicated to developing new therapeutic approaches, improving patient outcomes, and contributing to global medical knowledge. As a sponsor of clinical trials, Ruijin Hospital ensures adherence to the highest ethical standards and regulatory compliance, fostering an environment of collaboration and excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Trial Officials
Chundi Xu
Principal Investigator
Ruijin Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported